CG Oncology’s lease in Irvine is ending this month, according to a recent regulatory filing. The biopharmaceutical company, which is focused on treating bladder cancer, earlier this year moved its headquarters to Dallas, Texas after signing a lease for approximately eight years. Shares in the company were little changed at $76.20 today with a market cap of $6.7 billion (Nasdaq: CGON).